A 39-year-old experienced hair regrowth on his temples after switching from finasteride to topical RU58841 combined with 5% minoxidil. He also underwent stemcell treatment and noticed improvements, attributing the regrowth mainly to the change in treatment.
Hair cloning technology is advancing, with clinical trials for improved methods expected by 2028 and 2029, potentially offering a solution for hair loss if donor follicles remain. Organtech's expansion into other biotech areas may secure funding, but the effectiveness of cloning depends on the availability of androgen-resistant donor follicles.
A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.
Researchers finding that microRNA can potentially regrow 90% of lost hair, and the challenges involved in moving this research forward to human trials. Various treatments for hair loss, such as finasteride and minoxidil, have been discussed.
Hair follicles can be dormant and potentially revived with treatments like finasteride and minoxidil, but irreversible loss occurs if certain structures are destroyed. Early intervention is more effective, and additional methods like microneedling may help.
A user is considering exosome therapy from Springs Rejuvenation for hair loss after unsuccessful attempts with PRP, adipose injections, and a laser cap. They are intrigued by the therapy's potential and the clinic's guarantee of 30% improved coverage, despite concerns about FDA approval and high-pressure sales tactics.
Verteporfin is being explored for hair regeneration, with unofficial trials and updates shared online. Efforts are being made to encourage more surgeons to trial verteporfin for donor hair regeneration.
PP405 is a promising molecule that may reactivate dormant hair follicles, potentially offering a new treatment for hair loss. It is in phase 2 trials, with possible availability between 2027 and 2030.
ABS-201 shows promise for male hair regrowth by blocking the prolactin receptor, with higher expected efficacy than current treatments. The discussion also covers dosing differences between macaques and humans for hmi115, highlighting a significant dosage disparity.
RepliCel has purchased Trichoscience, and they have a video about hair multiplication. The conversation also mentions treatments like Minoxidil, finasteride, and RU58841.
Hair loss may be linked to the TRPS1 gene and protein, not just DHT. Amplifica's AMP-303 targets mesenchymal stemcells and shows promise in treating hair loss, unlike Pelage's PP405.
Exploring the idea of transplanting miniaturized hair follicles to healthier areas to potentially reverse hair loss, with concerns about DHT sensitivity and scar tissue formation. The conversation also humorously considers using mice for hair growth experiments.
PP405 may revive dormant hair follicles but is unlikely to help with long-term baldness where follicles are replaced by scar tissue. It is seen as a potential adjunct to treatments like minoxidil and finasteride, but its effectiveness on deeply fibrotic or scarred areas is doubtful.
The discussion is about using ASCEplus HRLB exosomes for hair loss treatment, which combines 10 billion exosomes with growth factors, nutrients, biotin, and copper tripeptide. The treatment is expensive and typically administered via scalp injections, but in Europe, it's done with microneedling.
PP405 shows promise in regenerating hair by activating dormant follicles. Other treatments like VDPHL01 and Breezula are also advancing, providing new hope for hair loss solutions.
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stemcells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
The conversation is about optimism for new hair loss treatments like Stemson's bioengineering, osteopotin, SCUBE3, GT20029, and Verteprofin, and inquires about other notable treatments.
Users discuss potential game-changing hair loss treatments in the next 10 years. Some mention KX-826, SCUBE3, and stemcells as promising options, while others express doubt due to past disappointments and lack of focused research.
Stress can lead to hair loss by affecting hair-follicle stemcells, and this loss is harder to recover from if one has male pattern baldness (MPB). Treatments like finasteride and minoxidil are used to address hair loss, but stress-related hair loss differs from androgenic alopecia.
A 20-year-old experiencing hair loss since age 16 is using finasteride and minoxidil and is considering future hair transplants. Discussions include the potential for multiple transplants, the use of body hair for coverage, and the importance of treatments like dutasteride and scalp micropigmentation for maintaining hair density.
Exosome injections stimulate hair growth by using exosomes' healing potential to awaken dormant hair follicles and promote new hair cell creation. The procedure increases scalp blood circulation, encourages collagen and elastin formation, and regenerates hair follicles, improving hair thickness and quality.
Adipose-derived stemcell secretome showed significant improvement in hair density and growth, especially when combined with minoxidil, suggesting a synergistic effect. The study had limitations, including a small sample size and potential bias.
A dermatologist recommended PRP (Platelet Rich Plasma) and GFC (Growth Factor Concentrate) for pattern baldness, but online sources suggest they may not be effective. The user is seeking opinions on these treatments.
User discusses verteporfin for hair regrowth through "super microneedling" and preventing scarring. They mention a case of an old man regrowing hair after a head injury and suggest verteporfin could recreate this result.
PP405 is a promising experimental topical treatment for alopecia that reactivates dormant hair follicles by targeting cellular energy, with large-scale trials planned for 2026. While it shows potential, it cannot regenerate permanently destroyed follicles, making hair transplants the only guaranteed solution for advanced baldness currently.
The conversation discusses concerns about the potential risk of cancer from creating new hair follicles through microneedling, due to stemcell division. Specific treatments mentioned include microneedling, caffeine-containing anti-hair loss shampoos, and other unspecified topicals.
Stemson Therapeutics has shut down, disappointing those seeking a hair loss cure. Current treatments like minoxidil, finasteride, and dutasteride are discussed, with some users experiencing side effects and exploring alternatives like PP405.
Microneedling with needle lengths of 1.5mm to 2.5mm to stimulate hair follicle stemcells for potential hair growth. Using needles longer than 2.5mm is not recommended due to risk of puncturing veins in the scalp. A dermastamp is suggested over a roller.